Cisplatin + nintedanib + pemetrexed + placebo

Author: vpsb

August undefined, 2024

WebDec 19, 2016 · ITT analysis of the primary end point showed that treatment with nintedanib plus pemetrexed resulted in a significant prolongation of PFS compared with placebo plus pemetrexed (4.4 vs. 3.6 months with a HR of 0.83 and a p value of 0.04). WebJul 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double …

Nintedanib in combination with pemetrexed and cisplatin …

WebThis is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by … WebJul 5, 2024 · Nintedanib, oral, triple angiokinase inhibitor of VEGFR, PDGFR, and FGFR, has been investigated in a phase II study randomizing patients who received first line pemetrexed-cisplatin between nintedanib or placebo. Recently, preliminary data were reported on the additional effect of nintedanib added to cisplatin/pemetrexed. impact grip head for lights and accessories

Efficacy of chemotherapy for malignant pleural mesothelioma …

WebGültigkeitsbereich: Leitlinie Tumorzentrum Oberösterreich Bronchuskarzinom Paz-Ares L, Gridelli C et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non- small-cell lung cancer (PARAMOUNT): a double-blind ... WebApr 1, 2024 · Request PDF On Apr 1, 2024, Antoinette J. Wozniak and others published Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Find, read and cite all ... WebNov 1, 2024 · Grosso, F. et al. Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized placebo-controlled LUME-meso trial. J. Clin. impact grease fitting cleaner

Tumour Treating Fields in combination with pemetrexed and cisplatin …

Clinical development of nintedanib for advanced non-small-cell …

Weband safety of nintedanib versus placebo, each in combination with up to 6 cycles of pemetrexed/cisplatin, followed by nintedanib or placebo maintenance, in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM)4 In Phase II, nintedanib demonstrated an improvement in the primary list slot machinesWebPatients received oral nintedanib (150 mg or 200 mg twice daily for 12 weeks) or placebo, in addition to usual neoadjuvant chemotherapy with intravenous gemcitabine 1000 mg/m 2 on days 1 and 8 and intravenous cisplatin 70 mg/m 2 on day 1 of a 3-weekly cycle. The primary endpoint was pathological complete response rate, assessed at cystectomy or ... lists markdown

"WebApr 11, 2024 · Nintedanib doses were permitted to be reduced to 150 mg, 100 mg, or 50 mg (or to 100 mg or 50 mg for patients with GFR 40–60 mL/min). Both gemcitabine and … " - Cisplatin + nintedanib + pemetrexed + placebo

Cisplatin + nintedanib + pemetrexed + placebo

LUME-Meso: Design and Rationale of the Phase III Part of …

WebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural … WebMay 30, 2024 · Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Anna K. Nowak. x. Anna K. Nowak. Search for articles by this author , Federica Grosso. x ...

Did you know?

WebDec 9, 2024 · Scagliotti GV, et al. Nintedanib in Combination with Pemetrexed and Cisplatin for Chemotherapy-Naive Patients with Advanced Malignant Pleural … WebDec 1, 2024 · Placebo, pemetrexed 500 mg/m 2, and investigator's choice of cisplatin 75 mg/m 2 or carboplatin AUC 5 mg/mL/min intravenously on Day 1 of each 21-day cycle for 4 cycles followed by placebo and pemetrexed 500 mg/m 2 intravenously every 3 weeks.

WebJun 5, 2024 · Nintedanib Chemo Combo Promising for Malignant Mesothelioma Frontline treatment with nintedanib plus pemetrexed and cisplatin improved progression-free … WebOct 1, 2024 · PDF On Oct 1, 2024, Federica Grosso and others published SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial Find ...

WebSep 18, 2024 · This study aims to evaluate the safety of nintedanib when used in combination with pemetrexed and cisplatin in patients with unresectable MPM. This randomized, double-blind, placebo-controlled, phase 3 trial included a total of 458 patients with unresectable epithelioid MPM. WebDec 4, 2014 · At least one dose reduction of nintedanib or placebo was required by 18.6% and 6.3% of patients in the nintedanib plus docetaxel and placebo plus docetaxel groups, respectively. Gastrointestinal AEs …

WebApr 16, 2024 · Patients in the pembrolizumab-combination group received pemetrexed, a platinum-based drug, and pembrolizumab; those in the placebo-combination group received pemetrexed, a platinum-based …

WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … impact group apprenticeshipsWebReview of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial J Thorac Dis . 2024 Sep;10(Suppl 26):S3124-S3127. doi: 10.21037/jtd.2024.07.105. impact green screen foldingWebPemetrexed (Alimta) is administered as 500 mg/m 2 as an intravenous infusion over 10 minutes after pembrolizumab and prior to carboplatin or cisplatin on day 1 of each 21-day cycle for 4 cycles for initial treatment of metastatic non-squamous NSCLC in individuals with a creatinine clearance of 45 mL/min or greater. impact grounds maintenance and design incWebJ Clin Oncol 31(23):2895–2902 CrossRef Paz-Ares LG et al (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. impact group busWebA subsequent analysis of the available intent-to-treat population based on independent review data showed a PFS benefit for patients treated with nintedanib plus pemetrexed compared with placebo plus pemetrexed (median PFS of 4.4 months versus 3.6 months; hazard ratio [HR] of 0.83 with a 95% confidence interval [CI] of 0.70–0.99; P=0.04), but ... impact grounds maintenanceWebNintedanib is an oral angiokinase inhibitor targeting multiple signaling pathways implicated in the pathogenesis of MPM, including the VEGF receptor. The phase III part of the … impact group dealer loginWebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus placebo. Nintedanib and placebo were continued until disease progression. The primary end point was PFS. Eighty-seven patients were randomly assigned 1:1 ratio. impact groundwork